Physician profile
Brittany Behm
NPI 1235424144
$5,693.72
in general payments reported to CMS, 2019-2025
28 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.95 · 2021: $96.43 · 2022: $985 · 2023: $1,079 · 2024: $1,649 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,512 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,512.30 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,136.30 | 2022-2025 | |
| Abbvie INC. | $1,019.23 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Novo Nordisk INC | $573.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $439.84 | 2023-2025 | Veozah |
| Lilly USA, LLC | $380.45 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $361.89 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $332.39 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.44 | 2022-2025 | Xifaxan |
| Abbott Laboratories | $180.53 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $152.93 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Kvk-Tech, INC. | $80.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.57 | 2022-2023 | Jardiance |
| Phathom Pharmaceuticals, INC. | $74.54 | 2024-2025 | Voquezna |
| Lundbeck LLC | $74.28 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $71.97 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $65.26 | 2025 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $63.24 | 2022 | |
| Axsome Therapeutics, INC. | $57.51 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $56.56 | 2024 | Spravato |
| Dexcom, INC. | $46.30 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $43.24 | 2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $33.69 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $24.17 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $22.14 | 2023 | Quviviq |
| Organon LLC | $20.20 | 2025 | Nexplanon |
| Inspire Medical Systems, INC. | $17.47 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $16.85 | 2022 | |
| Roche Diagnostics Corporation | $14.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Behm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.